Search
Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year
Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the lead program for oesophageal cancer will have data by the end of 2026.
5 hours ago
Infinitopes, a cancer vaccine company, describes their technology and what it means to be housed in Oxford's BioEscalator
Lian Ni Lee and Susannah de Jager discuss how quickly Infinitopes has been able to get ready for the clinic.
May 2, 2024
.png){kind=logo}
